earnings and quarter XXXX fourth call. our to full-year Welcome Erika. Thanks,
two programs significant I'm and say NanoFlu. we happy on In through programs. results So, beginning a you weeks Novavax's Phase advancing achieved few brief of the the first X the ResVax today's XXXX, an quarter team update XXXX important both we the have will lead that call for ago to be a our and and teleconference relatively has ResVax. via of focused because of provided concerning have results
RSV that delivered disease on The X RSV to clinical provide X in ResVax February, FDA year of approval licensure vaccine. preventing our trial. highlighted for this demonstrate to opportunity is accelerated a the successful the at we our NanoFlu of vaccine with earlier we the discuss first efficacy use Phase As call for the us the Phase end of results
now make during lines programs are XXXX. in of prepared our start that, an providing NanoFlu. for of advances we open call John meaningful summary program by Trizzino provide questions. overview We then to followed an both will update up our today's I'll ResVax on the a results. financial will After by
So let’s get overview. started with ResVax the
be with is globally mortality of in especially before, age. cause to infants for you overstate will discussed is RSV for in the one an in It months in developing infant cause second-leading the hospitalization of the length show of of at difficult it the life. under infants. leading rationale children we've the vaccine As Statistics that six U.S. first RSV year
Also were announce RSV the tract with did we efficacy associated significant ResVax to did endpoint, demonstrates the hospitalization in against statistically disappointed pre-specified not at infection consequences XX%. health global to criteria pre-specified which most RSV nearly highlight the important addressed of against of exploratory confidence of disease. severe prevent, improve results of band potential lower Although, primary meet with respiratory from lower the to vaccine the however Prepare XX% from our trial RSV endpoint
both and As mothers profile RSV infants. benign expected, safety in the appears of
and related influenced which to children rest found may measures. to the to immunity of United geographic both a was This efficacy babies lower As in in the timing relation to were we the world the continue we've be born in imbalance immunization RSV. where States review born seem that by have these in to data, of exposure most compared to
is policy makers. further of is XX% We six severe Prevention respiratory and a of and of XX% severe illnesses of hospitalizations that ResVax hypoxemia in regulators, all-cause and all-cause effects opinion hospitalization life. showed with clear and RSV through the presentations. expect publications robust immunized reduction discussion months mothers reduction more and in there very future key in the to provide healthcare key more leaders infants and details finding
to & other partners we leaders. represent addition families hospitalization we shared the hypoxemia, get impact mortality, have available disease completion in factors importance data the Gates health clinical results pediatric could In and burden the We a believe key we our benefits mission are a this and obvious globally. pleased the The major Since the reducing with unanimous infants infant which Foundation element of is Bill of much Melinda recognized material advance key of the of for the severe have opinion economic investigators RSV with on risk overall feedback their trial, for mortality. at our that health. of foundation's also that reducing infant these were of in
get to market? Given in these all demonstrates together authorities to is, can We of question other our data our minds the answer these believe detailed global the ResVax and with for results complete assessment what is discuss authorities intend supports goal regulatory understanding of do We these whether to licensure. briefing can data these on first, licensed Novavax put and documents support that data findings. regulatory with our
meetings, the the considered. based the regulatory made on paths during agencies following will be with discussions these Following recommendations and
could licensure applications. be marketing would we sufficient and submit data First, then the for
applications. Second, to we additional conduct the trial we to the and sufficient trial. data could third, need then applications post-licensure will for and Or submit data conduct with result include the the within may commitment be marketing the and the marketing confirmatory licensure
of the While will feedback. timely we any we one for and responses first develop plans of are prepared these hope on based we two responses, for
on planning I to European other said the call have February, are Agency authorities. our we with FDA, regulatory national in the discussions As and Medicines
this third have these of soon as or take of year. as to discussions to possible, the pressing quarter we but up, in are quarter time hopefully All second reasonably set them early
appropriate for smaller our large perhaps more assess in multinational vaccine different [or partner health includes the best and United capabilities [ph]. and vaccine our an hopefully global or program, sponsors companies partners continue regional provide with nations] ResVax update time. the will to parallel, multiple companies, We potential with progress Partnering one the combination at we geographies. on In
are partners new our you shortly we reach is partners types our will regulatory and will ongoing of discussions on I various more clarity. discussions regulatory get having conclusions proceed. We potential for with as of partnering An after keep all element these that these posted believe the and we progress. important how discussions
ResVax conclude me on by Let summarizing remarks few points. my key a
profile an by of Our consequences more ResVax preventing the exceptional It’s infection. to-date. serious safety RSV works stable, well vaccine vaccine has
more focusing or we are addressing continuing Switching on regulatory global pathways our one strategy. a to and execute to program. are gears NanoFlu on We partner
in a a encouraging Medicine competitor clinical last overdose. published agreed Phase data meeting, significantly results. reminder, subsequent England approval the we trial Data XXXX early that vaccine results. the acknowledged New the Journal available improved trial hemagglutinin the for These as significant accelerated and In of responses High-Dose distinction demonstrated a FDA with that pathway June for NanoFlu. be were stage started from in clinical As could Fluzone very leading compared NanoFlu X/X XXXX to
to U.S.-licensed safety influenza and formulations of immune of adults, a responses in the vaccine. of hemagglutinin post-marketing States, trials with to our well-controlled approval a immunogenicity licensed NanoFlu inhibition to with in responses clinical in with NanoFlu a to effectiveness. commitment clinical accelerated XX also and pathway This in [ph] strength] we X We various with Novavax viruses, Fluzone United vaccines High-Dose. As ago, the of HAI, healthy a including a against included comparator months tolerated drifted X,XXX without many top will know, elicited wild-type vigorous or couple endpoints Phase or a demonstrated NanoFlu improved demonstrate well trial age compares the fall the years established announced line the [core XXXX over. of and adjuvant positive results. when of confirmatory conducted quadrivalent immune of strains conduct meet designed Phase HXNX against formulations to to two were or you X NanoFlu antibody trial responses Matrix-M All allow conduct the trial significantly compared
you is the overdose United causes may and mortality strain most in currently As that morbidity remember, HXNX in the States.
now with meet FDA of trial of the approach data we of accelerated turn and agrees pivotal with to next with Phase X that approval I'll and the proposed design use call to the believe key financial present again results quarter. If successes pathway X, for these this X months with given we Phase in Phase confirm the the in over With the to the can overview potential X will the John discuss FDA Phase complete, our programs two trial. these update of couple X our We licensure.
